Milestone Pharmaceuticals Inc (NASDAQ: MIST)’s stock price has soared by 6.71 in relation to previous closing price of 1.64. globenewswire.com reported 2025-03-04 that MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) — Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 94,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to employment of four new hires.
Is It Worth Investing in Milestone Pharmaceuticals Inc (NASDAQ: MIST) Right Now?
The 36-month beta value for MIST is at 1.14. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MIST is 50.76M, and currently, shorts hold a 0.79% of that float. The average trading volume for MIST on March 05, 2025 was 742.39K shares.
MIST’s Market Performance
The stock of Milestone Pharmaceuticals Inc (MIST) has seen a 0.00% decrease in the past week, with a -10.71% drop in the past month, and a -12.06% fall in the past quarter. The volatility ratio for the week is 9.86%, and the volatility levels for the past 30 days are at 7.50% for MIST. The simple moving average for the past 20 days is -12.39% for MIST’s stock, with a 5.05% simple moving average for the past 200 days.
Analysts’ Opinion of MIST
Many brokerage firms have already submitted their reports for MIST stocks, with Rodman & Renshaw repeating the rating for MIST by listing it as a “Buy.” The predicted price for MIST in the upcoming period, according to Rodman & Renshaw is $9 based on the research report published on August 22, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see MIST reach a price target of $4, previously predicting the price at $8. The rating they have provided for MIST stocks is “Hold” according to the report published on June 20th, 2023.
Piper Sandler gave a rating of “Overweight” to MIST, setting the target price at $10 in the report published on April 22nd of the previous year.
MIST Trading at -13.34% from the 50-Day Moving Average
After a stumble in the market that brought MIST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.36% of loss for the given period.
Volatility was left at 7.50%, however, over the last 30 days, the volatility rate increased by 9.86%, as shares sank -12.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.82% upper at present.
During the last 5 trading sessions, MIST fell by -0.11%, which changed the moving average for the period of 200-days by +1.04% in comparison to the 20-day moving average, which settled at $1.9974. In addition, Milestone Pharmaceuticals Inc saw -25.85% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MIST
Current profitability levels for the company are sitting at:
- 50.34 for the present operating margin
- 1.68 for the gross margin
The net margin for Milestone Pharmaceuticals Inc stands at 49.27. The total capital return value is set at -0.56. Equity return is now at value -162.87, with -50.37 for asset returns.
Based on Milestone Pharmaceuticals Inc (MIST), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -0.58. The debt to equity ratio resting at 2.25. The interest coverage ratio of the stock is -12.42.
Currently, EBITDA for the company is -56.84 million with net debt to EBITDA at -1.06. When we switch over and look at the enterprise to sales, we see a ratio of -155.0. The receivables turnover for the company is -0.42for trailing twelve months and the total asset turnover is -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.40.
Conclusion
In conclusion, Milestone Pharmaceuticals Inc (MIST) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
